SPOTLIGHT -
For publicly traded managed care firms
Innovations in Pharmacy and Its Impact on Managed Care
Managing Directors of L.E.K. Consulting, Joe Johnson, Todd Clark and Brendan Mitchell introduce the innovations happening in pharmacy, more specifically disruptive innovations, and how they affect managed care. The team explained some of the innovations to be on the lookout for in the future, also.
Read More
The Silver Linings of the Pandemic Playbook: Telehealth, 'Whole-Person Health,' per Rodrigo Cerdá, M.D., M.P.H., of Independence Blue Cross
The senior vice president of health services and chief medical officer at Independence Blue Cross in Philadelphia discusses the spotlight that the COVID-19 pandemic put on behavioral health and Independence's integration of behavioral health into its coverage and care management in this month's episode of “What's on Your Mind?" podcast.
Listen
How Recognizing Outstanding Efforts in Mental Healthcare Can Benefit Patients, Providers
Below highlights ways to recognize outstanding mental healthcare providers and the benefits that come from these efforts.
What Reimbursable Remote Care Through New CMS CPT Codes Means For Patients
Briana Contreras, an editor of Managed Healthcare Executive, chats with Bronwyn Spira, CEO and founder of Force Therapeutics, in this week's episode about CMS' new CPT codes that were introduced in 2022.
Gene Therapy for Hemophilia Is Becoming a Reality. Who Will Write the Checks to Pay for It?
Hemgenix for hemophilia B is priced to cost $3.5 million per treatment. Roctavian for hemophilia A may be approved by the FDA in July and is likely to be priced to cost between $2 million and $3 million per treatment.
FDA Updates for the Week of March 20, 2023
FDA approvals this week include: novel treatment for invasive candidiasis, an accelerated approval to Zynyz for Merkel cell carcinoma, the high-concentration Humira biosimilar Hyrimoz, and extension of Evkeeza’s indication to include young children. The agency also issued two complete responses this week: for Incyte’s extended-release Jakafi and for AbbVie’s Parkinson’s therapy.
